MedTrace Logo

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

NCT01161472 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-06-28

Study results available
· View outcomes & findings →

Summary

The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.

Conditions

  • Healthy

Interventions

DRUG

4mg fesoterodine

4mg tablet once daily for 6 days

DRUG

8mg fesoterodine

4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days

DRUG

alprazolam 1mg

1mg tablet once on last day of treatment period at clinic

DRUG

Placebo

Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01161472 on ClinicalTrials.gov